dihydroergotamine (DHE 45, Migranal. Atzumi)

From Aaushi
Jump to navigation Jump to search

Introduction

Alias DHE 45. Dihydroergotamine mesylate.

Indications

Contraindications

pregnancy category = x

safety in lactation = -

Dosage

Injection: 1 mg/mL.

Nasal powder (Atzumi) FDA approved for treatment of acute migraine[5]

Pharmacokinetics

  • onset of action is 15-30 minutes
  • extensively metabolized by the liver
  • 1/2life is 1.3-3.9 hours
  • eliminated predominantly into the bile & feces

elimination via liver

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. Jump up to: 4.0 4.1 NEJM Knowledge+ Pain Management and Opioids: Recharge
  5. Jump up to: 5.0 5.1 George J Nasal Powder for Acute Migraine Gets FDA Nod. DHE treatment includes proprietary device technology. MedPage Today May 1, 2025 https://www.medpagetoday.com/neurology/migraines/115386

Database